Article
Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
British journal of haematology - 1 May 2008
Nahi H, Selivanova G, Lehmann S, Möllgård L, Bengtzen S, Concha H, Svensson A, Wiman K G, Merup M, Paul C
Abstract excerpt
TP53 is mutated in 10-20% of cases of chronic lymphocytic leukaemia (CLL) and 3-8% of cases of acute myeloid leukaemia (AML). Recently, two classes of compounds that restore the function of p53 in tumours have been described. PRIMA-1 (p53-dependent reactivation and induction of massive apoptosis) restores the wild-type conformation of mutant TP53, whereas RITA (reactivation of p53 and induction of tumour cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.